During the corresponding time, Theravance Biopharma Inc saw a revenue deteriorated by -20.86 % year on year, sequentially revenue grew by 17.13 %. While revenue at the Theravance Biopharma Inc 's corporate clients
Theravance Biopharma Inc's Comment on Sales, Marketing and Customers
The company operates in the US COPD patient market with YUPELRI (revefenacin) inhalation solution, a nebulized long-acting muscarinic antagonist approved for maintenance treatment of COPD. It addresses a segment of COPD patients in the US who require or prefer nebulized delivery for maintenance therapy. YUPELRI was co-developed with Viatris Inc., which leads its commercialization in the US and internationally, excluding China and adjacent territories. The company co-promotes YUPELRI in the US under a profit and loss sharing agreement with Viatris. Additionally, the company sold its remaining royalty interest in global net sales of TRELEGY to GSK plc and receives milestone payments related to TRELEGY sales. Commercial partners include Viatris Inc. and GSK plc.
Theravance Biopharma Inc’s Comment on Sales, Marketing and Customers
The company operates in the US COPD patient market with YUPELRI (revefenacin) inhalation solution, a nebulized long-acting muscarinic antagonist approved for maintenance treatment of COPD. It addresses a segment of COPD patients in the US who require or prefer nebulized delivery for maintenance therapy. YUPELRI was co-developed with Viatris Inc., which leads its commercialization in the US and internationally, excluding China and adjacent territories. The company co-promotes YUPELRI in the US under a profit and loss sharing agreement with Viatris. Additionally, the company sold its remaining royalty interest in global net sales of TRELEGY to GSK plc and receives milestone payments related to TRELEGY sales. Commercial partners include Viatris Inc. and GSK plc.
Sources:
Theravance Biopharma inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Theravance Biopharma inc’s corporate clients.
For your research, we’ve provided 9 tables on Theravance Biopharma inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
185.37 %